Close Menu

Japanese in vitro diagnostics firm Sysmex said this week that it has acquired a pair of German companies — molecular diagnostics services firm Inostics and flow cytometry specialist Partec — in a bid to bolster its personalized medicine and companion diagnostics development business.

In particular, Sysmex said that it plans to integrate Inostics' BEAMing molecular testing technology — which combines emulsion-based digital PCR with magnetic beads, hybridization, and flow cytometry — with Partec's highly automated flow cytometry platforms.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.

Jul
24
Sponsored by
Hologic

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.